Interestingly, the long‐term results of the fixed duration Total Therapy IV without the use of anti‐CD38 monoclonal antibodies showed a 40% 10‐year PFS rate among patients with low risk MM based on the gene expression profile [50]. This evidence concerns the gene CD38 and Miyoshi myopathy.